Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode

NCT02746367 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT02746367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02746367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Observational
Overall status
Completed
Start date
March 31, 2016
Completion date
November 8, 2018
Enrollment
261 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder, bipolar i and bipolar ii